Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Inclusion Criteria:

1. Provide written informed consent and be willing and, in the opinion of theinvestigator, able to adhere to all protocol requirements.

2. Males and females aged ≥ 18 at the time of providing written informed consent.

3. Diagnosis of post-COVID POTS, defined by both a preceding COVID-19 infection basedon confirmed historical documentation and onset of POTS symptoms developing within 4months after COVID-19 infection as defined per consensus criteria.

4. COMPASS-31 score of at least 40 at the Screening visit.

5. Positive confirmatory standardized standing test (ie, HR increase of ≥ 30 bpm [≥ 40bpm for participants aged 18 to 19 years] within 10 minutes in the absence oforthostatic hypotension) at the Screening visit.

Exclusion Criteria:

1. Treatment with Immunoglobulin G (IgG) or plasmapheresis within 12 weeks beforeScreening

2. Symptoms and / or diagnosis of or receiving treatment for POTS before COVID-19infection

3. Prior diagnosis of or receiving current treatment at Screening for the followingconditions (unless onset was related to the inciting POTS-associated COVID-19infection): certain neurologic, autoimmune, endocrine, cardiac, or other disorders,and pre-existing psychiatric disorders

4. Presence of active infections, including human immunodeficiency virus infection,hepatitis B, hepatitis C, active SARS-CoV-2 infection, or any uncontrolled systemicinfection